LEO Pharma A/S, a global leader in medical dermatology, today announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI (Psoriasis Area Severity Index) 100 score for longer than those who were treated with ustekinumab over 52 weeks.
The post-hoc analysis of the AMAGINE-2 and AMAGINE-3 studies “ which included 3,712 people with moderate-to-severe psoriasis “ shows that 90% of patients treated with brodalumab who achieved PASI 100 also experienced sustained PASI 100. In the same analysis, only 77% of patients treated with ustekinumab who achieved PASI 100 also experienced sustained PASI 100. Study authors measured ˜sustained PASI 100 as the time to inadequate response, based on a static physicians global assessment (sPGA) of ‰¥3 or persistent values of 2 over at least a 4-week period at or after week 16.1
Because the sub-populations of patients treated with brodalumab and ustekinumab in these studies had different baseline characteristics, the study authors did not apply statistical comparisons.
Newer treatments for moderate-to-severe psoriasis have made it possible for patients to completely clear their skin, but the disease fluctuates over time, so we wanted to explore how fast and for how long patients can count on having complete skin clearance, said Professor Llus Puig, Director, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Aut²noma de Barcelona. These results show that brodalumab can offer more patients a longer, more sustained period of complete skin clearance than ustekinumab. That difference can have a big impact on patients quality of life.
LEO Pharma A/S
Trine Juul Wengel, Global External Communications
+45 72 60 86 18